Analyst Price Targets — CANF
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 2, 2026 10:41 am | — | H.C. Wainwright | $8.00 | $4.63 | StreetInsider | Can-Fite BioPharma (CANF) PT Raised to $8 at H.C. WainwrightMember Login |
| May 12, 2026 10:14 am | Swayampakula Ramakanth | H.C. Wainwright | $5.00 | $3.36 | TheFly | Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright |
| April 15, 2025 11:02 am | James Molloy | Industrial Alliance Securities | $90.00 | $31.40 | TheFly | Can-Fite price target lowered to $4.50 from $12 at Alliance Global Partners |
| July 17, 2024 7:06 am | Jason Kolbert | EF Hutton | $200.00 | $73.20 | TheFly | Can-Fite BioPharma initiated with a Buy at EF Hutton |
Latest News for CANF
Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Australian Patent Office has allowed Patent Application No.
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced completion of enrolment of the first 247 patients in its pivotal Phase 3…
Can-Fite BioPharma Ltd. (NYSE:CANF) on Wednesday said its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma met its primary safety endpoint, with updated follow-up data showing durable overall survival in a subset of heavily pretreated patients.
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months Ramat Gan, Israel, July 01, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CANF.
U.S. House Trading
No House trades found for CANF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.